✦ LIBER ✦
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
✍ Scribed by Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik; Seth Sadis; Carol A. Connell; David Gruben; Sriram Krishnaswami; Gene Wallenstein; Bethanie E. Wilkinson; Samuel H. Zwillich
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 424 KB
- Volume
- 64
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.